** Pharma co Hikma up c.5.6 pct, 2nd top gainer onLondon's bluechip index & on track for sharpest move inover 1 mnth after brokerage TP hike
** Barclays says U.S. generics deal, announced in July,transforms Hikma's long-term growth profile and ups TP on stockto 2760p from 2050p, keeps "overweight" rating
** 8 of 12 brokerages rate the stock "buy" or higher, 3"hold" and 1 "sell" or lower; their median PT is $38.35
** Stock moved up by slew of brokerage after co boughtBoehringer Ingleheim's specialty generics drugs business in theU.S. for $2.65 bln
** Deal moves up outer FY earnings by >20 pct &revolutionizes future opportunities, Barclays writes
** Jordanian co's stock up 12.64 pct YTD, contrasting ac.7.7 pct fall in the FTSE-100 index
** Valuations in health cos across globe buoyed by a surgein deal-making this year; sector top in global M&A untilrecently overtaken by the commodity deal frenzy (esha.vaish@thomsonreuters.com)